AlcoVet GI Therapy Ladder
A stepwise, evidence-informed protocol for gastrointestinal recovery in dogs and cats — mapping enzyme stabilisation, fluid and microbiome restoration, and appetite rebuild to sequential clinical phases.
The Three-Phase Protocol
Phase 1 Clinical Selection: Standard vs Advanced Enzyme Support
Choose for: Acute indigestion, dietary transition, post-gastroenteritis, FPV enzyme support, post-antibiotic disruption, senior patients with reduced enzyme output. Simple to moderate cases.
Escalate to: EPI, fat malabsorption, steatorrhoea, multi-ingredient or legume-rich diet intolerances, IBD with broad enzyme deficit, chronic flatulence, post-pancreatitis, where Alcozyme monotherapy has not stabilised within 3–5 days.
Adequate enzymatic activity is the foundation of gastrointestinal recovery. When endogenous enzyme production is impaired — by illness, dietary change, surgery, stress or ageing — macronutrient breakdown becomes incomplete, resulting in malabsorption, nutrient loss and continued GI upset. Alcozyme bridges this deficit by providing exogenous Alpha Amylase and Pepsin to stabilise digestion before fluid and microbiome restoration (Phase 2) begins.
Key Indications
- Acute indigestion, malabsorption and post-prandial GI discomfort
- Post-gastroenteritis and post-parvoviral enteritis GI recovery
- FPV: enzyme support during active mucosal injury — supports early enteral feeding on a damaged gut epithelium
- Dietary transition — novel protein introduction or formula changes
- Post-antibiotic GI disruption — restoring enzymatic activity alongside probiotic support
- Senior patients — age-related decline in pancreatic and gastric enzyme secretion
- Post-surgical GI stasis — enzyme support for early enteral nutrition recovery
- Chronic GI sensitivity — adjunct support under veterinary management
Alcozyme Plus is the advanced clinical escalation of Alcozyme — formulated where standard two-enzyme support is insufficient for the presentation. Five enzymes (Alpha Galactosidase, Diastase, Bromelain, Pepsin and Lipase) deliver complete macronutrient coverage across proteins, fats, starches and fermentable complex carbohydrates. Lipase addresses the critical fat maldigestion component absent from standard Alcozyme; Alpha Galactosidase resolves oligosaccharide fermentation and gas; Bromelain adds anti-inflammatory mucosal support alongside protein digestion.
Key Indications — Escalate from Alcozyme when:
- Exocrine Pancreatic Insufficiency (EPI) — complete enzyme replacement including Lipase for fat maldigestion
- Fat malabsorption and steatorrhoea — Lipase-mediated triglyceride hydrolysis and fat-soluble vitamin absorption
- Multi-ingredient and legume-rich diets — Alpha Galactosidase addresses fermentable oligosaccharides (raffinose, stachyose) causing gas and bloating
- Inflammatory Bowel Disease (IBD) with digestive insufficiency — Bromelain anti-inflammatory action + full coverage
- Post-pancreatitis recovery — bridging the period of reduced pancreatic exocrine output
- Chronic flatulence and bloating — Alpha Galactosidase directly reduces colonic fermentation gas
- Senior patients with multi-enzyme decline — comprehensive address of pancreatic, gastric and intestinal enzyme output reduction
- Complex post-GE recovery — where Alcozyme standard has not stabilised within 3–5 days
GI illness rapidly depletes electrolytes and destabilises the intestinal microbiome. Fluid losses from diarrhoea and vomiting cause electrolyte imbalances — notably hypokalaemia — while broad-spectrum antibiotic therapy and mucosal injury disrupt commensal microbial diversity. Alcolyte Pro addresses both deficits simultaneously: sodium-glucose cotransport (SGLT-1) drives efficient oral rehydration, while multi-strain probiotic supplementation rebuilds gut microbiome diversity and supports mucosal barrier re-establishment. Phase 2 is initiated once vomiting is controlled and oral intake is tolerated.
Key Indications
- Mild to moderate dehydration from GI fluid loss — diarrhoea, vomiting, heat or exercise
- FPV: post-discharge oral rehydration and microbiome restoration — after IV fluids discontinued, when oral intake tolerated
- Post-antibiotic probiotic restoration — commensal microbiome rebuilding during and after antibiotic courses
- Dietary transition and food change GI upset — microbiome stabilisation during novel ingredient introduction
- Travel and boarding stress diarrhoea — oral electrolytes + probiotic support for transit gut upset
- Paediatric patients — kittens and puppies with limited fluid reserves at high risk of rapid deterioration
- Geriatric patients — electrolyte fragility and ongoing dysbiosis management in senior animals
- Ongoing probiotic maintenance in chronic IBD and recurrent GI sensitivity under veterinary guidance
Following GI stabilisation and rehydration, a significant proportion of patients remain inappetent — creating a progressive caloric deficit that extends recovery time and risks muscle catabolism and, particularly in cats, hepatic lipidosis. The cause is serotonin-mediated appetite suppression that persists beyond the resolution of active GI signs. OrexiGuard uses cyproheptadine's serotonin antagonist mechanism to directly counteract this suppression, stimulating voluntary food intake so nutritional rehabilitation and true recovery can begin. Phase 3 is initiated only after vomiting and diarrhoea have fully resolved.
Key Indications
- Post-stabilisation anorexia — GI signs fully resolved but voluntary feeding not resumed despite supportive care
- FPV: post-stabilisation appetite stimulation in cats and kittens — a recognised protocol component in FPV recovery
- Feline hepatic lipidosis prevention — early appetite intervention before fat mobilisation from adipose tissue begins
- Chronic illness-related inappetence — renal disease, IBD, neoplasia-associated anorexia
- Post-surgical and hospitalisation anorexia — particularly in cats following abdominal procedures
- Stress-induced inappetence — boarding, rehoming, multi-pet household changes
- Weight loss support in geriatric feline patients with progressive inappetence
- Chemotherapy-associated inappetence in dogs and cats under oncology supervision
Clinical Conditions & Phase Mapping
Full three-phase protocol applies. FPV has no antiviral therapy — management is entirely supportive. Phase 1 (Alcozyme) supports enzyme-assisted early enteral feeding during active mucosal injury; Phase 2 (Alcolyte Pro) provides oral rehydration and microbiome restoration at discharge; Phase 3 (OrexiGuard) addresses post-stabilisation anorexia in kittens and cats. See detailed FPV pathway below.
All three phases. Enzyme support during active illness, oral rehydration at discharge after IV fluids, appetite stimulation in the post-stabilisation recovery window.
Phase 1+ (Alcozyme Plus) primary — comprehensive enzyme replacement including Lipase. Long-term ongoing use. Phase 2 if microbiome co-disruption present (common in EPI).
Phases 1 and 2 typically sufficient. Alcozyme stabilises digestion; Alcolyte Pro corrects fluid and microbiome. Phase 3 if post-illness anorexia persists after signs resolve.
Phases 1 and 2. Alcozyme supports enzymatic adaptation during novel food introduction; Alcolyte Pro stabilises the microbiome during transition. Alcozyme Plus if plant-rich or legume-containing diet.
Phase 2 primary — Alcolyte Pro restores commensal microbial diversity during and after broad-spectrum antibiotic courses. Phase 1 (Alcozyme) if reduced enzyme activity also present.
Phase 1+ (Alcozyme Plus) for post-acute pancreatic enzyme bridge. Phase 2 if dysbiosis or fluid deficit present. Phase 3 if post-pancreatitis anorexia persists — veterinary supervision essential.
Phase 3 (OrexiGuard) critical — early cyproheptadine appetite intervention prevents fat mobilisation and lipid accumulation in the liver of anorexic cats. Early introduction is key to prevention.
Phase 1 (Alcozyme) supports early enteral nutrition on reduced gut motility. Phase 2 restores electrolytes and microbiome post-operatively. Phase 3 for post-surgical anorexia, especially in cats after abdominal procedures.
Phase 2 (Alcolyte Pro) primary — oral electrolytes and probiotics for stress-induced transit diarrhoea. Phase 1 for enzyme disruption; Phase 3 if inappetence persists after return home.
Phase 1+ (Alcozyme Plus) — Alpha Galactosidase directly reduces colonic fermentation of oligosaccharides from legumes and plant proteins. Phase 2 for co-existing dysbiosis.
All three phases often relevant concurrently. Age-related reduced pancreatic and gastric enzyme output (P1+), electrolyte fragility (P2), and chronic inappetence (P3) are common concurrent presentations in senior dogs and cats.
All phases under close veterinary supervision. Kittens and puppies have minimal fluid reserves and deteriorate rapidly with GI fluid loss. Early Phase 2 rehydration is critical; Phase 1 and 3 support full recovery.
Clinical Application: Feline Panleukopenia (FPV) Full Pathway
FPV — Entirely Supportive Management
Feline panleukopenia virus (FPV) destroys intestinal crypt epithelium and causes profound panleukopenia — one of the most life-threatening GI emergencies in unvaccinated cats and kittens. There is no direct antiviral therapy. Survival depends entirely on supportive care quality. The AlcoVet GI Therapy Ladder maps onto all three clinical windows of FPV management — active inpatient illness, post-IV discharge, and post-stabilisation recovery. Mortality in untreated or poorly supported kittens approaches 90%; with appropriate supportive care, survival rates significantly improve. All FPV cases require urgent veterinary assessment and inpatient management.
Why Alcozyme in FPV Phase 1
- FPV selectively targets and destroys rapidly dividing intestinal crypt cells — the precursor cells that regenerate the absorptive villous epithelium. This profoundly impairs endogenous digestive enzyme secretion and nutrient absorption capacity for the duration of the active viral injury phase.
- Current evidence supports early cautious enteral nutrition in FPV management — gastric feeding stimulates mucosal regeneration, prevents bacterial translocation and supports immune function. Alcozyme's Alpha Amylase and Pepsin support macronutrient digestion on the damaged, regenerating mucosa, reducing the digestive load when endogenous enzyme output is impaired.
- Alpha Amylase bridges the carbohydrate digestion deficit, supporting caloric recovery from small enteral feeds during the early refeeding window. Pepsin supports protein breakdown essential for the amino acid supply needed for mucosal regeneration.
- Concurrent use with Alcolyte Pro (Phase 2) is appropriate once oral intake is established, even during inpatient management, under veterinary supervision.
Why Alcolyte Pro in FPV Phase 2
- Electrolyte disturbances — particularly severe hypokalaemia — are one of the primary life-threatening complications of FPV. Hypokalaemia impairs cardiac function and muscle contractility; its correction alongside rehydration is a central pillar of FPV management. Alcolyte Pro's SGLT-1-driven oral electrolyte formulation continues potassium and sodium correction during the home recovery phase after IV therapy is discontinued.
- FPV infection causes profound intestinal microbiome destruction — the virus eliminates rapidly dividing crypt cells that support commensal microbial community structure, and IV broad-spectrum antibiotics (essential to prevent translocation) further deplete the microbiome. Multi-strain probiotic supplementation in Alcolyte Pro accelerates commensal microbial diversity recovery, restores colonocyte-nourishing short-chain fatty acid production, and supports mucosal barrier re-establishment.
- SGLT-1 cotransport allows continued fluid and electrolyte absorption even through a partially regenerating mucosa — particularly important in the discharge window when the gut epithelium is still recovering but IV fluids have been stopped.
Why OrexiGuard in FPV Phase 3
- Post-FPV anorexia is a recognised and clinically significant complication — kittens and cats frequently refuse food even after resolution of active clinical signs. The stress response, gut dysbiosis, and illness-associated serotonin signalling all contribute to persistent appetite suppression that outlasts the active disease phase.
- In cats, even short periods of anorexia can precipitate hepatic lipidosis as fat is mobilised from adipose stores and overwhelms the liver's processing capacity. Post-FPV kittens — often already cachectic from the illness — are at particularly high risk. Early appetite stimulation is a critical component of preventing secondary hepatic complications.
- Cyproheptadine's serotonin (5-HT2) antagonist mechanism directly counteracts the serotonin-mediated appetite suppression, stimulating hypothalamic appetite centres to resume voluntary feeding. This is a well-characterised use of cyproheptadine in feline medicine and is part of standard FPV recovery protocols in veterinary practice.
- OrexiGuard supports resumption of voluntary food intake, enabling the caloric and protein intake necessary for mucosal regeneration, immune system recovery, and complete nutritional rehabilitation.
Complete FPV Supportive Care Pathway — Alcozyme → Alcolyte Pro → OrexiGuard
Used together across the three clinical phases, AlcoVet's GI Therapy Ladder provides complete supportive care for feline panleukopenia recovery — from enzyme-supported early enteral feeding during active viral mucosal injury, through discharge-phase oral rehydration and microbiome restoration, to appetite stimulation in the post-stabilisation window. All three phases have distinct evidence bases and non-overlapping mechanisms. Full protocol and clinical reference documentation available on request.
Clinical Decision Guide — Which Phases to Use
Simple Acute GI Upset
Single episode of vomiting or diarrhoea, mild, diet-related. No systemic signs. Resolves within 24–48 hours.
Moderate GI Illness — Post-Recovery Anorexia
Gastroenteritis, resolved but patient not eating. GI signs gone but voluntary feeding not resumed after 24–48 hours.
Complex Maldigestion — EPI / Fat Malabsorption
EPI diagnosis, steatorrhoea, fat-rich diet, post-pancreatitis. Full macronutrient coverage essential.
Plant-Rich / Legume Diet Intolerance
Commercial diet with peas, lentils, chickpeas, legumes. Gas, bloating, loose stools after meals. Multi-ingredient diet sensitivity.
Post-Antibiotic Gut Disruption
Patient on or completing broad-spectrum antibiotics. Loose stools, microbiome depletion, no active infection signs.
Anorexic Cat — Hepatic Lipidosis Risk
Cat not eating for 48+ hours. No active vomiting or diarrhoea. Overweight cat or known previous liver disease especially at risk.
Senior Patient — Concurrent Multi-Phase Decline
Geriatric dog or cat with reduced enzyme output, electrolyte fragility and chronic inappetence as concurrent presentations.
Post-Surgical Abdominal Case
Feline or canine patient post-abdominal surgery. Reduced gut motility, early enteral feeding required, post-op anorexia common.
Neonatal / Paediatric Emergency
Kitten or puppy with GI signs. Minimal fluid reserves, rapid deterioration risk. All phases relevant under close veterinary supervision.
Stock the complete GI Therapy Ladder. Alcozyme, Alcozyme Plus, Alcolyte Pro and OrexiGuard — stepwise GI recovery products for every clinical presentation. Available pan-India to veterinary stockists. Request samples, clinical protocol materials or stockist terms.
The GI Therapy Ladder is the clinical framework for AlcoVet's Gastro Care portfolio — complete stepwise recovery support for dogs and cats.